These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 25800974)
1. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus. Baran B; Soyer OM; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Karaca C; Demir K; Besisik F; Onel D; Gulluoglu M; Badur S; Kaymakoglu S Liver Int; 2015 Oct; 35(10):2265-74. PubMed ID: 25800974 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients. Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833 [TBL] [Abstract][Full Text] [Related]
4. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329 [TBL] [Abstract][Full Text] [Related]
5. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
6. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
8. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance. Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753 [TBL] [Abstract][Full Text] [Related]
9. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
10. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL; J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191 [TBL] [Abstract][Full Text] [Related]
11. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912 [TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Baran B; Soyer OM; Ormeci AC; Gokturk S; Evirgen S; Bozbey HU; Akyuz F; Karaca C; Demir K; Besisik F; Onel D; Gulluoglu M; Badur S; Kaymakoglu S Antimicrob Agents Chemother; 2013 Apr; 57(4):1790-6. PubMed ID: 23380725 [TBL] [Abstract][Full Text] [Related]
15. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518 [TBL] [Abstract][Full Text] [Related]
16. Tenofovir in the treatment of naïve and refractory chronic Hepatitis B: A single center experience in Saudi Arabia. Alsohaibani F; Alturaif N; Abdulshakour A; Alghamdi S; Alshaibani A; Alashgar H; Alkahtani K; Kagevi I Saudi J Gastroenterol; 2015; 21(5):295-9. PubMed ID: 26458856 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300 [TBL] [Abstract][Full Text] [Related]
18. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704 [TBL] [Abstract][Full Text] [Related]
19. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J; J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139 [TBL] [Abstract][Full Text] [Related]
20. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]